Turkiye Klinikleri Journal of Internal Medicine

.: REVIEW
Moleküler Yönleriyle Karaciğer Gelişimi
Liver Development with Molecular Aspects
Tuğba ÇELİK SAMANCIa, Alpaslan GÖKÇİMENa
aHistoloji ve Embriyoloji AD, Aydın Adnan Menderes Üniversitesi Tıp Fakültesi, Aydın, TÜRKİYE
Turkiye Klinikleri J Intern Med. 2019;4(1):32-42
doi: 10.5336/intermed.2018-64016
Article Language: TR
Full Text
ÖZET
 Vücudun en büyük iç organı ve bezi olan karaciğer metabolik, endokrin ve ekzokrin olmak üzere oldukça önemli işlevlere sahiptir. Karbonhidrat, protein ve yağ metabolizmasını düzenlemekte, endokrin olarak albumin, globulinler, lipoproteinler, protrombin ve fibrinojen gibi proteinleri, ekzokrin olarak safra salgılamaktadır. Karaciğerin embriyonik gelişimi trilaminar germ diski oluşumunu takiben üçüncü haftanın ortası ve dördüncü haftanın başında ön bağırsağın kaudal parçasındaki hepatik divertikülden gerçekleşmektedir. Hepatik divertikülden gelişen karaciğer tomurcuğu hepatoblastları içermektedir. Hepatoblastlar hem karaciğerin parankimini oluşturan hepatositlere hem de safra kanalikülünü döşeyen safra epitelyal hücreleri olan kolanjiyositlere farklılaşma özelliğindedirler. Karaciğer parankimini oluşturan hepatositlerin arasında yer alan sinüzoidler anjiyogenez ile oluşmaktadır. Sinüzoid duvarında yer alan karaciğer makrofajları, Kupffer hücreleri mezenşimden köken almaktadır. Tüm bu gelişim aşamalarında çeşitli transkripsiyon faktörleri, proteinler, genler ve sinyal yolakları birliktelik göstermektedir. Bu çalışmada, moleküler yönleriyle ilişkili olarak karaciğerin embriyonik gelişimi detaylı olarak sunulmaktadır. Karaciğerin embriyonik gelişim sürecinin moleküler mekanizmasının net bir şekilde anlaşılmasının ve elde edilen veriler doğrultusunda multidisipliner uygulamaların bir arada kullanımının karaciğer hastalıklarının tedavisinde umut verici sonuçlar oluşturabileceği düşünülmektedir.

Anahtar Kelimeler: Karaciğer; embriyonik gelişim
ABSTRACT
 The liver is the largest internal organ and gland in the body which has very important functions including metabolic, endocrine and exocrine. It has also function carbohydrate, protein and fat metabolism as metabolically, endocrine albumin synthesis, globulins, lipoproteins prothrombin, proteins such as fibrinogen is given to the blood as well as bile exocrine function. The embryonic development of the liver occurs from the hepatic diverticulum in the caudal part of the foregut at the beginning of the third week and the 4th week following the formation of the trilaminar germ disc. Liver bud which developed from hepatic diverticulum contains hepatoblasts. Hepatoblasts are differentiated both to hepatocytes that form the parenchyma of the liver and to biliary epithelial cells (cholangiocytes) laying the bile canaliculus. Sinusoids, which are located among the hepatocytes that form the liver parenchyma, are also formed by angiogenesis. Kupffer cells, which are liver macrophages located in the perisinusoidal space called the disse range of liver tissue originate from the mesenchyme. Various transcription factors, proteins, genes and signaling pathways are associated in all these stages of development. In this review, liver development with molecular aspects is also presented in detail. It is though that a clear understanding of the molecular mechanisms involved in the embryonic development of the liver and in combination with multidisciplinary applications may provide promising results in the treatment of liver disease.

Keywords: Liver; embryonic development
REFERENCES:
  1. Langman Medikal Embriyoloji. In: Sadler TW, ed. Başaklar AC, çeviri editörü. 11. Baskı. Ankara: Palme Yayıncılık; 2010. p.400.
  2. Wells JM, Melton DA. Early mouse endoderm is patterned by soluble factors from adjacent germ layers. Development. 2000;127(8):1563-72. [PubMed ]
  3. Shen MM. Nodal signaling: developmental roles and regulation. Development. 2007;134 (6):1023-34. [Crossref ] [PubMed]
  4. Zorn AM, Wells JM. Molecular basis of vertebrate endoderm development. Int Rev Cytol. 2007;259:49-111. [Crossref ]
  5. Liu JX, Xu QH, Li S, Yu X, Liu W, Ouyang G, et al. Transcriptional factors Eaf1/2 inhibit endoderm and mesoderm formation via suppressing TGF-β signaling. Biochim Biophys Acta Gene Regul Mech. 2017;1860(10):1103-16. [Crossref ] [PubMed]
  6. Fan X, Hagos EG, Xu B, Sias C, Kawakami K, Burdine RD, et al. Nodal signals mediate interactions between the extra-embryonic and embryonic tissues in zebrafish. Dev Biol. 2007;310(2):363-78. [Crossref] [PubMed] [PMC]
  7. Hyde CE, Old RW. Regulation of the early expression of the Xenopus nodal-related 1 gene, Xnr1. Development. 2000;127:1221-9. [PubMed]
  8. Xanthos JB, Kofron M, Wylie C, Heasman J. Maternal VegT is the initiator of a molecular network specifying endoderm in Xenopus laevis. Development. 2001;128(2):167-80. [PubMed]
  9. Crompton MR, Bartlett TJ, MacGregor AD, Manfioletti G, Buratti E, Giancotti V, et al. Identification of a novel vertebrate homeobox gene expressed in haematopoietic cells. Nucleic Acids Res. 1992;20(21):5661-7. [Crossref] [PubMed] [PMC]
  10. Ohlsson H, Karlsson K, Edlund T. IPF1, a homeodomain-containing transactivator of the insulin gene. EMBO J. 1993;12(11):4251-9. [Crossref] [PubMed] [PMC]
  11. Zeng X, Yutzey KE, Whitsett JA. Thyroid transcription factor-1, hepatocyte nuclear factor-3 beta and surfactant protein A and B in the developing chick lung. J Anat. 1998;193(Pt 3):399-408. [Crossref] [PubMed] [PMC]
  12. Ehrman LA, Yutzey KE. Anterior expression of the caudal homologue cCdx-B activates a posterior genetic program in avian embryos. Dev Dyn. 2001;221(4):412-21. [Crossref] [PubMed]
  13. Grapin-Botton A. Antero-posterior patterning of the vertebrate digestive tract: 40 years after Nicole Le Douarin's PhD thesis. Int J Dev Biol. 2005;49(2-3):335-47.
  14. Tremblay KD, Zaret KS. Distinct populations of endoderm cells converge to generate the embryonic liver bud and ventral foregut tissues. Dev Biol. 2005;280(1):87-99. [Crossref ] [PubMed]
  15. Moore-Scott BA, Opoka R, Lin SC, Kordich JJ, Wells JM. Identification of molecular markers that are expressed in discrete anterior-posterior domains of the endoderm from the gastrula stage to mid-gestation. Dev Dyn. 2007;236(7):1997-2003. [Crossref ] [ PubMed]
  16. Roberts DJ, Johnson RL, Burke AC, Nelson CE, Morgan BA, Tabin C. Sonic hedgehog is an endodermal signal inducing Bmp-4 and Hox genes during induction and regionalization of the chick hindgut. Development. 1995;121(10):3163-74. [PubMed ]
  17. Tiso N, Filippi A, Pauls S, Bortolussi M, Argenton F. BMP signalling regulates anteroposterior endoderm patterning in zebrafish. Mech Dev. 2002;118(1-2):29-37. [Crossref ]
  18. Kumar M, Jordan N, Melton D, Grapin-Botton Signals from lateral plate mesoderm instruct endoderm toward a pancreatic fate. Dev Biol. 2003;259(1):109-22. [Crossref ]
  19. Chen Y, Pan FC, Brandes N, Afelik S, Sölter M, Pieler T. Retinoic acid signaling is essential for pancreas development and promotes endocrine at the expense of exocrine cell differentiation in Xenopus. Dev Biol. 2004;271(1):144-60. [Crossref ] [PubMed]
  20. Stafford D, Hornbruch A, Mueller PR, Prince VE. A conserved role for retinoid signaling in vertebrate pancreas development. Dev Genes Evol. 2004;214(9):432-41. [Crossref] [PubMed]
  21. Martin MA, Bhatia M. Analysis of the human fetal liver hematopoietic microenvironment. Stem Cells Dev. 2005;14(5):493-504. [Crossref] [ PubMed]
  22. Dessimoz J, Opoka R, Kordich JJ, Grapin-Botton A, Wells JM. FGF signaling is necessary for establishing gut tube domains along the anterior-posterior axis in vivo. Mech Dev. 2006;123(1):42-55. [Crossref ] [PubMed]
  23. McLin VA, Rankin SA, Zorn AM. Repression of Wnt/beta-catenin signaling in the anterior endoderm is essential for liver and pancreas development. Development. 2007;134(12): 2207-17. [Crossref ] [PubMed]
  24. Goessling W, North TE, Lord AM, Ceol C, Lee S, Weidinger G, et al. APC mutant zebrafish uncover a changing temporal requirement for wnt signaling in liver development. Dev Biol. 2008;320(1):161-74. [Crossref ] [PubMed]
  25. Wills A, Dickinson K, Khokha M, Baker JC. Bmp signaling is necessary and sufficient for ventrolateral endoderm specification in Xenopus. Dev Dyn. 2008;237(8):2177-86. [Cross - ref ] [PubMed] [PMC]
  26. Wang J, Rhee S, Palaria A, Tremblay KD. FGF signaling is required for anterior but not posterior specification of the murine liver bud. Dev Dyn. 2015;244(3):431-43. [Crossref] [PubMed] [ PMC]
  27. Zaret KS. Liver specification and early morphogenesis Mech Dev. 2000;92(1):83-8. [Crossref]
  28. Zaret KS. Hepatocyte differentiation: from the endoderm and beyond. Curr Opin Genet Dev. 2001;11(5):568-74. [Crossref ]
  29. Zaret KS, Grompe M. Generation and regeneration of cells of the liver and pancreas. Science. 2008;322(5907)1490-4. [Crossref] [PubMed] [PMC]
  30. Zaret KS, Carroll JS. Pioneer transcription factors: establishing competence for gene expression. Genes Dev. 2011;25(21):2227-41. [Crossref] [PubMed] [PMC]
  31. Gualdi R, Bossard P, Zheng M, Hamada Y, Coleman JR, Zaret KS. Hepatic specification of the gut endoderm in vitro: cell signalling and transcriptional control. Genes Dev. 1996;10(13):1670-82. [Crossref ] [ PubMed]
  32. Bossard P, Zaret KS. GATA transcription factors as potentiators of gut endoderm differentiation. Development. 1998;125(24):4909-17. [PubMed ]
  33. Bossard P, Zaret KS. Repressive and restrictive mesodermal interactions with gut endoderm: possible relation to Meckel's Diverticulum. Development. 2000;127(22):4915-23. [PubMed ]
  34. Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M, Zaret KS. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell. 2002;9(2):279-89. [Crossref ]
  35. Lee CS, Friedman JR, Fulmer JT, Kaestner KH. The initiation of liver development is dependent on Foxa transcription factors. Nature. 2005;16;435(7044):944-7.
  36. Sekiya T, Muthurajan UM, Luger K, Tulin AV, Zaret KS. Nucleosome-binding affinity as a primary determinant of the nuclear mobility of the pioneer transcription factor FoxA. Genes Dev. 2009;23(7):804-9. [Crossref][ PubMed] [PMC]
  37. Kuo CT, Morrisey EE, Anandappa R, Sigrist K, Lu MM, Parmacek MS, et al. GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev. 1997;118):1048-60.
  38. Molkentin JD, Lin Q, Duncan SA, Olson EN. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev. 1997;11(8):1061-72. [Crossref] [PubMed]
  39. Zhao R, Watt AJ, Li J, Luebke-Wheeler J, Morrisey EE, Duncan SA. GATA6 is essential for embryonic development of the liver but dispensable for early heart formation. Mol Cell Biol. 2005;25(7):2622-31. [Crossref] [PubMed] [PMC]
  40. Watt AJ, Zhao R, Li J, Duncan SA. Development of the mammalian liver and ventral pancreas is dependent on GATA4. BMC Dev Biol. 2007;7:37. [Crossref ] [PubMed] [PMC]
  41. Zhang L, He JB. Progress of GATA6 in liver development. Yi Chuan. 2018;40(1):22-32. [PubMed]
  42. Rossi JM, Dunn NR, Hogan BL, Zaret KS. Distinct mesodermal signals, including BMPs from the septum transversum mesenchyme, are required in combination for hepatogenesis from the endoderm. Genes Dev. 2001;15(15):1998-2009. [Crossref ] [PubMed] [PMC]
  43. Chung WS, Shin CH, Stainier DY. Bmp2 signaling regulates the hepatic versus pancreatic fate. Dev Cell. 2008;15(5):738-48. [Crossref ] [PubMed] [PMC]
  44. Lupien M, Eeckhoute J, Meyer CA, Wang QB, Zhang Y, Li W, et al. FoxA1 translates epigenetic signatures into enhancer-driven lineagespecific transcription. Cell. 2008;132:958-70. [Crossref] [PubMed] [PMC]
  45. Xu CR, Cole PA, Meyers DJ, Kormish J, Dent S, Zaret KS. Chromatin ?prepattern? and histone modifiers in a fate choice for liver and pancreas. Science. 2011;332(6032):963-6. [Crossref] [PubMed] [PMC]
  46. Shin D, Lee Y, Poss KD, Stainier DY. Restriction of hepatic competence by Fgf signaling. Development. 2011;138(7):1339-48. [Cross ref] [PubMed] [PMC]
  47. Zaret KS. Regulatory phases of early liver development: paradigms of organogenesis. Nat Rev Genet. 2002;3(7):499-512. [Crossref] [PubMed]
  48. Zaret KS, Watts J, Xu E, Wandzioch E, Smale ST, Sekiya T. Pioneer factors, genetic competence,and inductive signaling: programming liver and pancreas progenitors from the endoderm. Cold Spring Harb Symp Quant Biol. 2008;73:119-26. [Crossref] [PubMed] [PMC]
  49. North TE, Goessling W. Endoderm specification, liver development, and regeneration. Methods Cell Biol. 2011;101:205-23. [Crossref] [PubMed]
  50. Duncan SA, Watt AJ. BMPs on the road to hepatogenesis. Genes Dev. 2001;15(15):1879-84. [Crossref ] [PubMed]
  51. Calmont A, Wandzioch E, Tremblay KD, Minowada G, Kaestner KH, Martin GR, et al. An FGF response pathway that mediates hepatic gene induction in embryonic endoderm cells. Dev Cell. 2006;11(3):339-48. [Crossref] [PubMed]
  52. Bort R, Signore M, Tremblay K, Martinez Barbera JP, Zaret KS. Hex homeobox gene controls the transition of the endoderm to a pseudostratified, cell emergent epithelium for liver bud development. Dev Biol. 2006;290(1): 44-56. [Crossref ] [PubMed]
  53. Margagliotti S, Clotman F, Pierreux CE, Lemoine P, Rousseau GG, Henriet P, et al. Role of metalloproteinases at the onset of liver development. Dev Growth Differ. 2008;50(5): 331-8. [Crossref ] [PubMed]
  54. Shiojiri N, Sugiyama Y. Immunolocalization of extracellular matrix components and integrins during mouse liver development. Hepatology. 2004;40(2):346-55. [Crossref ] [PubMed]
  55. Tatsumi N, Miki R, Katsu K, Yokouchi Y. Neurturin-GFRalpha2 signaling controls liver bud migration along the ductus venosus in the chick embryo. Dev Biol. 2007;307(1):14-28. [Crossref] [PubMed]
  56. Matsumoto K, Yoshitomi H, Rossant J, Zaret KS. Liver organogenesis promoted by endothelial cells prior to vascular function. Science. 2001;294(5542):559-63. [Crossref] [PubMed]
  57. Keng VW, Yagi H, Ikawa M, Nagano T, Myint Z, Yamada K, et al. Homeobox gene Hex is essential for onset of mouse embryonic liver development and differentiation of the monocyte lineage. Biochem Biophys Res Commun. 2000;276(3):1155-61. [Crossref ] [PubMed]
  58. Duncan SA. Generation of embryos directly from embryonic stem cells by tetraploid embryo complementation reveals a role for GATA factors in organogenesis. Biochem Soc Trans. 2005;33(Pt 6):1534-6. [Crossref ] [PubMed]
  59. Zhao R, Watt AJ, Battle MA, Li J, Bondow BJ, Duncan SA. Loss of both GATA4 and GATA6 blocks cardiac myocyte differentiation and results in acardia in mice. Dev Biol. 2008;317(2): 614-9. [Crossref ] [PubMed] [PMC]
  60. Sosa-Pineda B, Wigle JT, Oliver G. Hepatocyte migration during liver development requires Prox1. Nat Genet. 2000;25(3):254-5. [Crossref] [PubMed]
  61. Burke Z, Oliver G. Prox1 is an early specific marker for the developing liver and pancreas in the mammalian foregut endoderm. Mech Dev. 2002;118(1-2):147-55. [Crossref ]
  62. Clotman F, Lannoy VJ, Reber M, Cereghini S, Cassiman D, Jacquemin P, et al. The onecut transcription factor HNF6 is required for normal development of the biliary tract. Development. 2002;129(8):1819-28. [PubMed]
  63. Jacquemin P, Lemaigre FP, Rousseau GG. The Onecut transcription factor HNF-6 (OC-1) is required for timely specification of the pancreas and acts upstream of Pdx-1 in the specification cascade. Dev Biol. 2003;258(1): 105-16. [Crossref ]
  64. Jacquemin P, Pierreux CE, Fierens S, van Eyll JM, Lemaigre FP, Rousseau GG. Cloning and embryonic expression pattern of the mouse Onecut transcription factor OC-2. Gene Expr Patterns. 2003;3(5):639-44. [Crossref ]
  65. Pierreux CE, Vanhorenbeeck V, Jacquemin P, Lemaigre FP, Rousseau GG. The transcription factor hepatocyte nuclear factor-6/Onecut-1 controls the expression of its paralog Onecut-3 in developing mouse endoderm. J Biol Chem. 2004;279(49):51298-304. [Cross - ref ] [ PubMed]
  66. Margagliotti S, Clotman F, Pierreux CE, Beaudry JB, Jacquemin P, Rousseau GG, et al. The Onecut transcription factors HNF6/OC-1 and OC-2 regulate early liver expansion by controlling hepatoblast migration. Dev Biol. 2007;311(2):579-89. [Crossref] [PubMed]
  67. Fruman DA, Mauvais-Jarvis F, Pollard DA, Yballe CM, Brazil D, Bronson RT, et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat Genet. 2000;26(3):379-82. [Crossref ] [PubMed]
  68. Reimold AM, Etkin A, Clauss I, Perkins A, Friend DS, Zhang J, et al. An essential role in liver development for transcription factor XBP1. Genes Dev. 2000;14(2):152-7. [PubMed] [PMC]
  69. Watanabe T, Nakagawa K, Ohata S, Kitagawa D, Nishitai G, Seo J, et al. SEK1/MKK4-mediated SAPK/JNK signaling participates in embryonic hepatoblast proliferation via a pathway different from NF-kappaB-induced anti-apoptosis. Dev Biol. 2002;250(2):332-47. [Cross - ref] [PubMed]
  70. Chen Y, Jürgens K, Hollemann T, Claussen M, Ramadori G, Pieler T. Cell-autonomous and signal-dependent expression of liver and intestine marker genes in pluripotent precursor cells from Xenopus embryos. Mech Dev. 2003;120(3):277-88. [Crossref ]
  71. Krupczak-Hollis K, Wang X, Kalinichenko VV, Gusarova GA, Wang IC, Dennewitz MB, et al. The mouse Forkhead Box m1 transcription factor is essential for hepatoblast mitosis and development of intrahepatic bile ducts and vessels during liver morphogenesis. Dev Biol. 2004;276(1):74-88. [Crossref ] [PubMed]
  72. Suzuki A, Sekiya S, Büscher D, Izpisúa Belmonte JC, Taniguchi H. Tbx3 controls the fate of hepatic progenitor cells in liver development by suppressing p19ARF expression. Development. 2008;135(9):1589-95. [Crossref] [PubMed]
  73. Lemaigre F, Zaret KS. Liver development update: new embryo models, cell lineage control, and morphogenesis. Curr Opin Genet Dev. 2004;14(5):582-90. [Crossref ] [PubMed]
  74. Mikula M, Schreiber M, Husak Z, Kucerova L, Ruth J, Wieser R, et al. M. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J. 2001;20(8):1952-62. [Crossref] [PubMed] [PMC]
  75. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature. 1995;376(6536):167-70. [Crossref] [PubMed]
  76. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NFkappaB activation. Nature. 2000:406(6791): 86-90. [Crossref ] [PubMed]
  77. Abshagen K, Eipel C, Kalff JC, Menger MD, Vollmar B. Loss of NF-kappaB activation in Kupffer cell-depleted mice impairs liver regeneration after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol. 2007;292 (6):1570-7. [Crossref ] [PubMed]
  78. Gunes C, Heuchel R, Georgiev O, Muller KH, Lichtlen P, Blüthmann H, et al. Embryonic lethality and liver degeneration in mice lacking the metal-responsive transcriptional activator MTF-1. EMBO J. 1998;17(10):284-54. [Crossref ] [PubMed] [PMC]
  79. Eferl R, Sibilia M, Hilberg F, Fuchsbichler A, Kufferath I, Guertl B, et al. Functions of c-Jun in liver and heart development. J Cell Biol. 1999;145(5):1049-61. [Crossref] [PubMed] [PMC]
  80. Li J, Ning G, Duncan SA. Mammalian hepatocyte differentiation requires the transcription factor HNF-4alpha. Genes Dev. 2000;14 (4):464-74. [PubMed ] [PMC]
  81. Parviz F, Matullo C, Garrison WD, Savatski L, Adamson JW, Ning G, et al. Hepatocyte nu clear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet. 2003;34(3):292-6. [Crossref ] [PubMed]
  82. Watt AJ, Garrison WD, Duncan SA. HNF4: a central regulator of hepatocyte differentiation and function. Hepatology. 2003;37(6): 1249-53. [Crossref ] [PubMed]
  83. Satohisa S, Chiba H, Osanai M, Ohno S, Kojima T, Saito T, et al. Behavior of tight-junction, adherens-junction and cell polarity proteins during HNF-4alpha-induced epithelial polarization. Exp Cell Res. 2005;310(1):66-78. [Crossref] [PubMed]
  84. Battle MA, Konopka G, Parviz F, Gaggl AL, Yang C, Sladek FM, et al. Hepatocyte nuclear factor 4 alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver. Proc Natl Acad Sci U S A. 2006;103(22):8419-24. [Crossref] [PubMed] [PMC]
  85. Konopka G, Tekiela J, Iverson M, Wells C, Duncan SA. Junctional adhesion molecule-A is critical for the formation of pseudocanaliculi and modulates E-cadherin expression in hepatic cells. J Biol Chem. 2007;282(38):28137-48. [Crossref ] [PubMed]
  86. Wang ND, Finegold MJ, Bradley A, Ou CN, Abdelsayed SV, Wilde MD, et al. Impaired energy homeostasis in C/EBP alpha knockout mice. Science. 1995;269(5227):1108-12. [Crossref] [PubMed]
  87. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell. 1996;84(4):575-85. [Crossref]
  88. Weinstein M, Monga SP, Liu Y, Brodie SG, Tang Y, Li C, et al. Smad proteins and hepatocyte growth factor control parallel regulatory pathways that converge on beta1-integrin to promote normal liver development. Mol Cell Biol. 2001;21(15):5122-31. [Crossref] [PubMed] [PMC]
  89. Monga SP, Monga HK, Tan X, Mulé K, Pediaditakis P, Michalopoulos GK. Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology. 2003;124(1): 202-16. [Crossref ] [ PubMed]
  90. Hussain SZ, Sneddon T, Tan X, Micsenyi A, Michalopoulos GK, Monga SP. Wnt impacts growth and differentiation in ex vivo liver development. Exp Cell Res. 2004;292(1):157-69. [Crossref] [PubMed]
  91. Clotman F, Jacquemin P, Plumb-Rudewiez N, Pierreux CE, Van der Smissen P, Dietz HC, et al. Control of liver cell fate decision by a gradient of TGF beta signaling modulated by Onecut transcription factors. Genes Dev. 2005;19(16):1849-54. [Crossref] [PubMed] [PMC]
  92. Clotman F, Lemaigre FP. Control of hepatic differentiation by activin/TGFbeta signaling.Cell Cycle. 2006;5(2):168-71. [Crossref] [PubMed]
  93. Decaens T, Godard C, de Reyniès A, Rickman DS, Tronche F, Couty JP, et al. Stabilization of beta-catenin affects mouse embryonic liver growth and hepatoblast fate. Hepatology. 2008;47(1):247-58. [Crossref] [PubMed]
  94. Geisler F, Nagl F, Mazur PK, Lee M, ZimberStrobl U, Strobl LJ, et al. Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice. Hepatology. 2008;48(2):607-16. [Crossref] [PubMed]
  95. Zong Y, Panikkar A, Xu J, Antoniou A, Raynaud P, Lemaigre F, et al. Notch signaling controls liver development by regulating biliary differentiation. Development. 2009;136(10): 1727-39. [Crossref ] [PubMed] [PMC]
  96. 96. Monaghan AP, Kaestner KH, Grau E, Schütz G. Postimplantation expression patterns indicate a role for the mouse forkhead/Hnf-3 alpha, beta and gamma genes in determination of the definitive endoderm, chordamesoderm and neuroectoderm. Development. 1993;119(3):567-78. [PubMed]
  97. Flodby P, Barlow C, Kylefjord H, AhrlundRichter L, Xanthopoulos KG. Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein alpha. Biol Chem. 1996;271(40): 24753-60. [Crossref ]
  98. Kamiya A, Kinoshita T, Miyajima A. Oncostatin M and hepatocyte growth factor induce hepatic maturation via distinct signaling pathways. FEBS Lett. 2001;492(1-2):90-4. [Crossref]
  99. Elvevold K, Smedsrød B, Martinez I. The liver sinusoidal endothelial cell: a cell type of controversial and confusing identity. Am J Physiol Gastrointest Liver Physiol. 2008;294(2):G391-400. [Crossref ] [PubMed]
  100. Collardeau-Frachon S, Scoazec JY. Vascular development and differentiation during human liver organogenesis. Anat Rec (Hoboken). 2008;291(6):614-27. [Crossref ] [PubMed]
  101. Mouta Carreira C, Nasser SM, di Tomaso E, Padera TP, Boucher Y, Tomarev SI, et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res. 2001;61(22):8079-84. [PubMed]
  102. Lalor PF, Lai WK, Curbishley SM, Shetty S, Adams DH. Human hepatic sinusoidal endothelial cells can be distinguished by expression of phenotypic markers related to their specialised functions in vivo. World J Gastroenterol. 2006;12(34):5429-39. [Crossref] [PubMed ] [PMC]
  103. Klein D, Demory A, Peyre F, Kroll J, Augustin HG, Helfrich W, et al. Wnt2 acts as a cell typespecific, autocrine growth factor in rat hepatic sinusoidal endothelial cells cross-stimulating the VEGF pathway. Hepatology. 2008;47(3): 1018-31. [Crossref ] [PubMed]
  104. Enzan H, Himeno H, Hiroi M, Kiyoku H, Saibara T, Onishi S. Development of hepatic sinusoidal structure with special reference to the Ito cells. Microsc Res Tech. 1997;39(4): 336-49. [Crossref]
  105. Yamane A, Seetharam L, Yamaguchi S, Gotoh N, Takahashi T, Neufeld G, et al. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene. 1994;9(9):2683-90. [PubMed]
  106. Yoshida M, Nishikawa Y, Omori Y, Yoshioka T, Tokairin T, McCourt P, et al. Involvement of signaling of VEGF and TGF-beta in differentiation of sinusoidal endothelial cells during culture of fetal rat liver cells. Cell Tissue Res. 2007;329(2):273-82. [Crossref ] [ PubMed]
  107. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88(1):125-72. [Crossref] [PubMed] [PMC]
  108. Pérez-Pomares JM, Carmona R, GonzálezIriarte M, Macías D, Guadix JA, MuñozChápuli R. Contribution of mesotheliumderived cells to liver sinusoids in avian embryos. Dev Dyn. 2004;229(3):465-74. [Cross - ref ] [PubMed]
  109. Yin C, Evason KJ, Asahina K, Stainier DYR. Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest. 2013;123(5):1902-10. [Crossref] [PubMed] [PMC]
  110. Loo CK, Wu XJ. Origin of stellate cells from submesothelial cells in a developing human liver. Liver Int. 2008;28(10):1437-45. [Crossref ] [PubMed]
  111. Asahina K, Tsai SY, Li P, Ishii M, Maxson RE Jr, Sucov HM, et al. Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development. Hepatology. 2009;49(3): 998-1011. [Crossref] [PubMed] [PMC]
  112. Kolterud A, Wandzioch E, Carlsson L. Lhx2 is expressed in the septum transversum mesenchyme that becomes an integral part of the liver and the formation of these cells is independent of functional Lhx2. Gene Expr Patterns. 2004;4(5):521-8. [Crossref ] [PubMed]
  113. Asahina K, Zhou B, Pu WT, Tsukamoto H. Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. Hepatology. 2011;53(3):983-95. [Crossref] [PubMed] [PMC]
  114. Wandzioch E, Kolterud A, Jacobsson M, Friedman SL, Carlsson L. Lhx2?/? mice develop liver fibrosis. Proc Natl Acad Sci U S A. 2004;101(47):16549-54. [Crossref ] [PubMed] [PMC]
  115. Ijpenberg A, Pérez-Pomares JM, Guadix JA, Carmona R, Portillo-Sánchez V, Macías D, et al. Wt1 and retinoic acid signaling are essential for stellate cell development and liver morphogenesis. Dev Biol. 2007;312(1):157-70. [Crossref] [PubMed]
  116. Naito M, Hasegawa G, Ebe Y, Yamamoto T. Differentiation and function of Kupffer cells. Med Electron Microsc. 2004;37(1):16-28. [Crossref] [PubMed]
  117. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336,(6077):86-90. [Crossref ] [PubMed]
  118. Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38(1):79-91. [Crossref][PubMed] [PMC]
  119. Ren X, Hogaboam C, Carpenter A, Colletti L. Stem cell factor restores hepatocyte proliferation in IL-6 knockout mice following 70% hepatectomy. J Clin Investig. 2003;112(9):1407-18. [Crossref] [PubMed] [PMC]
  120. Khan AA, Parveen N, Mahaboob VS, Rajendraprasad A, Ravindraprakash HR, Venkateswarlu J, et al. Safety and efficacy of autologous bone marrow stem cell transplantation through hepatic artery for the treatment of chronic liver failure: a preliminary study. Transplant Proc. 2008;40(4):1140-4. [Crossref] [PubMed]
  121. Mark AL, Sun Z, Warren DS, Lonze BE, Knabel MK, Melville Williams GM, et al. Stem cell mobilization is life saving in an animal model of acute liver failure. Ann Surg. 2010;252(4): 591-6. [Crossref ]
  122. Takami T, Terai S, Sakaida I. Stem cell therapy in chronic liver disease. Curr Opin Gastroenterol. 2012;28(3):203-8. [Crossref] [PubMed]
  123. Soto-Gutierrez A, Navarro-Alvarez N, Zhao D, Rivas-Carrillo JD, Lebkowski J, Tanaka N, et al. Differentiation of mouse embryonic stem cells to hepatocyte-like cells by co-culture with human liver nonparenchymal cell lines. Nat Protoc. 2007;2(2):347-56. [Crossref] [PubMed]
  124. Si-Tayeb K, Noto FK, Nagaoka M, Li JX, Battle MA, Duris C, et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology. 2010;51(1):297-305. [Crossref] [PubMed] [PMC]
  125. Stock P, Bruckner S, Ebensing S, Hempel M, Dollinger MM, Christ B. The generation of hepatocytes from mesenchymal stem cells and engraftment into murine liver. Nat Protoc. 2010;5(4):617-27. [Crossref ] [ PubMed]
  126. Du Y, Wang, J, Jia J, Song N, Xiang C, Xu J, et al. Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming. Cell Stem Cell. 2014;14(3): 394-403. [Crossref ] [PubMed]
  127. Huang, P, Zhang L, Gao Y, He Z, Yao D, Wu Z, et al. Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. Cell Stem Cell. 2014;14(3):370-84. [Crossref ] [PubMed]
  128. Gerbal-Chaloin S, Funakoshi N, Caillaud A, Gondeau C, Champon B, Si-Tayeb K. Human induced pluripotent stem cells in hepatology: beyond the proof of concept. Am J Pathol. 2014;184(2):332-47. [Crossref ] [PubMed]
  129. Rezvani M, Grimm AA, Willenbring H. Assessing the therapeutic potential of lab-made hepatocytes. Hepatology. 2016;64(1):287-94. [Crossref] [PubMed] [PMC]
  130. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature. 2013;499 (7459):481-4. [Crossref ] [PubMed]
  131. Camp JG, Sekine K, Gerber T, Loeffler-Wirth H, Binder H, Gac M, et al. Multilineage communication regulates human liver bud development from pluripotency. Nature. 2017;546(7659):533-38. [Crossref ] [PubMed]
  132. Soto-Gutiérrez A, Kobayashi N, Rivas-Carrillo JD, Navarro-Alvarez N, Zhao D, Okitsu T, et al. Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes. Nat Biotechnol. 2006;24(11):1412-9. [Crossref ] [ PubMed]
  133. Soto-Gutiérrez A, Navarro-Alvarez N, Zhao D, Rivas-Carrillo JD, Lebkowski J, Tanaka N, et al. Differentiation of mouse embryonic stem cells to hepatocyte-like cells by co-culture with human liver nonparenchymal cell lines. Nat Protoc. 2007;2(2):347-56. [Crossref] [PubMed]
  134. Dvir-Ginzberg M, Gamlieli-Bonshtein I, Agbaria R, Cohen S. Liver Tissue engineering within alginate scaffolds:effects of cellseeding density on hepatocyte viability, morphology, and function. Tissue Eng. 2003;9(4):757-66. [Crossref ] [PubMed]
  135. Levenberg S, Huang NF, Lavik E, Rogers AB, Itskovitz-Eldor J, Langer R. Differentiation of human embryonic stem cells on three-dimensional polymer scaffolds. Proc Natl Acad Sci USA. 2003;100:12741-6. [Crossref] [PubMed] [PMC]
  136. Li N, Zhang Q, Gao S, Song Q, Huang R, Wang L, et al. Three dimensional graphene foam as a biocompatible and conductive scaffold for neural stem cells. Sci Rep. 2013;3:1604. [Crossref ] [PubMed] [PMC]
  137. Qi CX, Yan XJ, Huang CY, Melerzanov A, Du YA. Biomaterials as carrier, barrier and reactor for cell-based regenerative medicine. Protein Cell. 2015;6:638-53. [Crossref ] [PubMed] [PMC]
  138. Li X, Tzeng SY, Liu X, et al. Nanoparticle mediated transcriptional modification enhances neuronal differentiation of human neural stem cells following transplantation in rat brain. Biomaterials. 2016;84:157-66. [Crossref] [PubMed] [PMC]

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com